Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  3. KRYS

(KRYS)

0.00

0.00 (0.00%)

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile
Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?
19.03.2026

Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025
22.02.2026

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025

Redmile Group bought 16,317 shares of Krystal Biotech; the estimated trade size was $3.43 million based on average closing prices in the fourth quarter. The quarter-end value of the Krystal Biotech position increased by $50.33 million, reflecting both trading and price movement effects.

Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark
18.02.2026

Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark

KRYS beats Q4 estimates as Vyjuvek sales jump 17%. It secures 660+ U.S. reimbursements and advances the gene therapy pipeline into 2026.

Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript
17.02.2026

Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript

Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript

Krystal: Profitable Growth And The Expanding Reach Of HSV-1 Technology
17.02.2026

Krystal: Profitable Growth And The Expanding Reach Of HSV-1 Technology

Krystal Biotech remains a "Buy" as VYJUVEK's strong launch powers profitability, and pipeline catalysts offer further upside. Krystal Biotech's valuation is underpinned by VYJUVEK's blockbuster trajectory, high gross margins (94%), and disciplined R&D and SG&A spending. Phase 1 KB407 data in cystic fibrosis confirms molecular proof-of-concept, with a $2B+ opportunity targeting modulator-ineligible and suboptimal responder patients.

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
17.02.2026

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong balance sheet, ending the quarter with $955.9 million in cash and investments PITTSBURGH, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business update. “In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to build the global infrastructure required to scale our impact,” said Krish S.

Got $300? 2 Biotech Stocks to Buy and Hold Forever
16.02.2026

Got $300? 2 Biotech Stocks to Buy and Hold Forever

Krystal Biotech pioneered the first topical gene therapy. ARS Pharmaceuticals introduced the first needle-free therapy to treat anaphylaxis.

Videos

No Data

There is no data to display

Press releases

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
17.02.2026

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong balance sheet, ending the quarter with $955.9 million in cash and investments PITTSBURGH, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business update. “In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to build the global infrastructure required to scale our impact,” said Krish S.

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
11.01.2026

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced selected preliminary unaudited 2025 financial results, including fourth quarter and full year 2025 VYJUVEK® net product revenue, and outlined the Company's strategic vision to drive the next stage of growth of its rare disease business.

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
25.07.2025

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
24.07.2025

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally reverse the biology of aging skin, announced today positive safety and efficacy results, including significant improvements in key skin aesthetic attributes such as wrinkles and elasticity, in PEARL-2, a randomized, double-blind, placebo-controlled Phase 1 study evaluating KB304, for the treatment of wrinkles of the décolleté. Meaningful aesthetic improvements were reported following KB304 treatment with clear and statistically significant advantages over placebo as evaluated by both the investigator and subjects using the Global Aesthetic Improvement Scale (GAIS).